Latest news with #Keon
Belfast Telegraph
14-07-2025
- Belfast Telegraph
Police probing separate overnight lorry arson incidents in Belfast and Larne
Police said two incidents took place in Larne and Belfast during the morning. The first incident happened in the Carryduff area at around 1.50am. PSNI Detective Inspector Keon said: 'We received a report at around 1.50am this morning, Monday, 14th July, of a lorry on fire in the Mill Road area of Carryduff. 'Officers attended, along with colleagues from the Northern Ireland Fire and Rescue Service. 'One vehicle sustained damage as a result of the fire, which is being treated as deliberate.' In the second incident in Larne, two lorries were set alight in the Ballymena Road area at around 4.15am. In Pictures - large amounts of rubbish left after Twelfth celebrations A PSNI spokesperson added: 'One lorry was substantially damaged with the second sustaining minor damaged. 'This is being treated as arson and anyone who may have witnessed anyone suspicious in the area or anyone with CCTV or other footage that could assist with enquiries, is asked to contact police on 101 quoting reference 296 14/07/25.'
Yahoo
10-07-2025
- Business
- Yahoo
Canadian pharmaceutical industry alarmed after Trump floats 200 per cent tariff
WASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril. "Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals," said Canadian Generic Pharmaceutical Association president Jim Keon. On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India. A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month. Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the U.S., Keon said. Such a low volume shouldn't trigger any U.S. concerns about an overreliance on imports, Keon said. He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal. "We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves," Keon said. But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country. Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market. Drugmakers have said that tariffs on pharmaceuticals could also cause shortages in the United States and increase costs for Americans who need medicine. "I think as a Canadian industry and as part of a global industry, we've been operating without tariffs for the last several decades and imposing tariffs is going to increase costs and complicate supply chains," Keon said. Keon said there is support for the Trump administration launching separate studies looking for ways to reduce prices and make the U.S. a more attractive market for drug manufacturing. Certain measures like harmonizing regulatory standards with those of other countries would help reduce unnecessary costs, he said. This report by The Canadian Press was first published July 9, 2025. Kelly Geraldine Malone, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Observer
10-07-2025
- Business
- National Observer
Canadian pharmaceutical industry alarmed after Trump hints at a 200 per cent tariff
Canada likely isn't the main target of US President Donald Trump 's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril. "Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals," said Canadian Generic Pharmaceutical Association president Jim Keon. On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India. A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month. Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the US, Keon said. Such a low volume shouldn't trigger any US concerns about an overreliance on imports, Keon said. He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal. "We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves," Keon said. But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country. Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market. Drugmakers have said that tariffs on pharmaceuticals could also cause shortages in the United States and increase costs for Americans who need medicine. "I think as a Canadian industry and as part of a global industry, we've been operating without tariffs for the last several decades and imposing tariffs is going to increase costs and complicate supply chains," Keon said. Keon said there is support for the Trump administration launching separate studies looking for ways to reduce prices and make the US a more attractive market for drug manufacturing. Certain measures like harmonizing regulatory standards with those of other countries would help reduce unnecessary costs, he said.
Vancouver Sun
10-07-2025
- Business
- Vancouver Sun
Canadian pharmaceutical industry alarmed after Trump threatens 200% tariff on drug imports
WASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril. 'Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals,' said Canadian Generic Pharmaceutical Association president Jim Keon. On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India. A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month. Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the U.S., Keon said. Such a low volume shouldn't trigger any U.S. concerns about an overreliance on imports, Keon said. He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal. 'We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves,' Keon said. But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country. Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market. Drugmakers have said that tariffs on pharmaceuticals could also cause shortages in the United States and increase costs for Americans who need medicine. 'I think as a Canadian industry and as part of a global industry, we've been operating without tariffs for the last several decades and imposing tariffs is going to increase costs and complicate supply chains,' Keon said. Keon said there is support for the Trump administration launching separate studies looking for ways to reduce prices and make the U.S. a more attractive market for drug manufacturing. Certain measures like harmonizing regulatory standards with those of other countries would help reduce unnecessary costs, he said. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here .
Winnipeg Free Press
09-07-2025
- Business
- Winnipeg Free Press
Canadian pharmaceutical industry alarmed after Trump floats 200 per cent tariff
WASHINGTON – An pharmaceutical industry representative says Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports — but his plan could still put parts of the Canadian sector in peril. Canadian Generic Pharmaceutical Association president Jim Keon says there's a risk that Canada will get caught in the crossfire as Trump pushes to reduce Americans' reliance on drugs imported from places like China and India. On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Keon says Canadian exports amount to less than five per cent of all generic medicines sold in the U.S. But without access to the American market, he says, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market. Monday Mornings The latest local business news and a lookahead to the coming week. Keon says there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. This report by The Canadian Press was first published July 9, 2025.
